COVID-19 Information On Therapeutics
Early treatment and post-exposure prophylaxis
Monoclonal antibody treatment can be used in people 12 years of age and older who weigh at least 88 pounds (40 kg) who are at high risk for severe COVID-19, including hospitalization or death for:
- Treatment of mild to moderate symptoms of COVID-19. To be eligible, patients must:
- Test positive for SARS-CoV-2.
- Be within 7 days of the start of their symptoms.
- Not be hospitalized.
- NIH statement for the treatment of COVID 19 in non-hospitalized patients.
- NIH statement to help prioritization when supplies are low.
**1/25/22, the government announced no further shipments of BAM/ETE or REGEN-COV for current and future cycles. FDA no longer recommends the use of Regeneron-COV and BAM/ETE. Please see this link for the latest update regarding therapeutics.
**4/5/2022 Sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant.
**NOTE**: No product returns will be accepted at this time; HHS has directed all facilities to keep their stock on hand until we receive further guidance.
Ritonavir boosted nirmatrelavir (Paxlovid) and molnupiravir (Lagevrio) were approved under EUA by the FDA for treatment of early COVID 19 infection. These treatments should be given within the first 5 days of symptom onset.
Paxlovid and molnupiravir may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which these drugs belong (i.e., anti-infectives).
Available COVID-19 Antivirals are covered by most insurance, typically resulting in no out-of-pocket expense.
**ORAL ANTIVIRAL TREATMENTS ARE DRIVE-THRU OR CURBSIDE ONLY! PLEASE DO NOT ENTER STORES!**
Pre Exposure Prophylaxis
A new monoclonal antibody (tixagevimab/cilgavimab) for the prevention of COVID-19 has been authorized by the FDA under EUA that may be used in immunocompromised patients and patients who have a medical contraindication to receiving a vaccine for COVID-19. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts